After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?

① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.

cls.cnDec 13 16:28

When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?

① Due to the difficulty of research and development and the slow progress, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the Peramivir dry powder inhaler project. At the same time, due to stricter approval processes, the Peramivir inhalation solution project will be postponed for two years. ② Given the multiple competition faced by the Peramivir injection, the adjustments to the new drug project will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.

cls.cnDec 12 16:11

Jinyu bio-technology: The industry is in the lowest valley period in history. New products next year will contribute to revenue growth | Directly addressing the earnings conference.

①At the performance briefing, jinyu bio-technology's chairman Zhang Chongyu frankly admitted that the industry is currently experiencing the lowest trough in history; ②The company stated that the competition in the pig vaccine sector is intense, and it will maintain its market share. Several new vaccines will be launched in the next two years. It is expected that the new products next year will contribute to a certain increase in revenue.

cls.cnNov 28 18:50

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement

① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.

cls.cnNov 27 21:14

Insurance capital is intensively increasing stakes in dividend stocks! What is the reason?

Currently, there are quite a few shareholders of insurance funds that hold more than 5% of the circulating shares of listed companies. In addition to some being unlocked restricted shares, there have also been many actions of shareholding and new stakes taken, with at least 14 instances of such actions this year.

China brokerageNov 20 09:58